Immunogenicity and safety of influenza vaccination in cancer patients receiving checkpoint inhibitors targeting PD-1 or PD-L1

Bayle, Arnaud; Khettab, Mohamed; Lucibello, Francesca; Chamseddine, Ali N.; Goldschmidt, Vincent; Perret, Audrey; Ropert, Stanislas; Scotté, Florian; Loulergue, Pierre; Mir, Olivier

doi:10.1016/j.annonc.2020.03.290

Cited by 32 publications

(34 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In fact, ICIs have already been used beyond cancer to treat, for example, sepsis-induced immunosuppression [ 73 , 74 ]. Moreover, ICIs have been confirmed to be safe when administered to cancer patients vaccinated for influenza virus [ 75 , 76 ]. In line with this concept, three additional independent clinical studies are currently enrolling non-cancer COVID-19 patients to test the efficacy of administering ICIs to reshape the impaired immune system of SARS-CoV-2 infected individuals (i.e., NCT04268537; NCT04356508 and NCT04413838).…”

Section: Our Hypothesis: Using Ici-blockade In Cancer Patients Durmentioning

confidence: 99%

Cancer Management during COVID-19 Pandemic: Is Immune Checkpoint Inhibitors-Based Immunotherapy Harmful or Beneficial?

Vivarelli

Falzone

Grillo

et al. 2020

Cancers

View full text Add to dashboard Cite

The coronavirus disease 2019 (COVID-19) is currently representing a global health threat especially for fragile individuals, such as cancer patients. It was demonstrated that cancer patients have an increased risk of developing a worse symptomatology upon severe acute respiratory syndrome associated coronavirus-2 (SARS-CoV-2) infection, often leading to hospitalization and intensive care. The consequences of this pandemic for oncology are really heavy, as the entire healthcare system got reorganized. Both oncologists and cancer patients are experiencing rescheduling of treatments and disruptions of appointments with a concurrent surge of fear and stress. In this review all the up-to-date findings, concerning the association between COVID-19 and cancer, are reported. A remaining very debated question regards the use of an innovative class of anti-cancer molecules, the immune checkpoint inhibitors (ICIs), given their modulating effects on the immune system. For that reason, administration of ICIs to cancer patients represents a question mark during this pandemic, as its correlation with COVID-19-associated risks is still under investigation. Based on the mechanisms of action of ICIs and the current evidence, we suggest that ICIs not only can be safely administered to cancer patients, but they might even be beneficial in COVID-19-positive cancer patients, by exerting an immune-stimulating action.

show abstract

Section: Our Hypothesis: Using Ici-blockade In Cancer Patients Durmentioning

confidence: 99%

Cancer Management during COVID-19 Pandemic: Is Immune Checkpoint Inhibitors-Based Immunotherapy Harmful or Beneficial?

Vivarelli

Falzone

Grillo

et al. 2020

Cancers

View full text Add to dashboard Cite

show abstract

“…ICIs have been already used beyond cancer for the treatment of, for example, sepsis-induced immunosuppression (131,132). Moreover, ICIs were safely administered to cancer patients vaccinated for influenza virus (133,134). Overall, ICIs are a promising tool to be studied against infective diseases, including SARS-CoV-2 (135,136).…”

Section: Immune-checkpoint Inhibitors Against Covid-19: a Lesson Learmentioning

confidence: 99%

Immune-checkpoint inhibitors from cancer to COVID‑19: A promising avenue for the treatment of patients with COVID‑19 (Review)

et al. 2020

View full text Add to dashboard Cite

“… 22 Similarly, if the reported seroconversion rate of patients with cancer undergoing chemotherapy ranged from 8% to 28%, 23 that reported for patients with cancer undergoing immune checkpoint blockade was higher, ranging from 60% to 70%. 24 25 The limitations of such analyses were the small sample size and the lack of correlation with the clinical efficacy of vaccination, which was not investigated in these case series. To address the issue, an ancillary analysis of the INVIDIa-2 trial (INVIDIa-bios substudy 26 ) allowed to collect serial serum samples and peripheral blood mononuclear cells samples of 130 subjects enrolled.…”

Section: Discussionmentioning

confidence: 96%

INfluenza Vaccine Indication During therapy with Immune checkpoint inhibitors: a multicenter prospective observational study (INVIDIa-2)

Bersanelli

Giannarelli

Giorgi

et al. 2021

J Immunother Cancer

View full text Add to dashboard Cite

BackgroundUntil now, no robust data supported the efficacy, safety and recommendation for influenza vaccination in patients with cancer receiving immune checkpoint inhibitors (ICIs).MethodsThe prospective multicenter observational INfluenza Vaccine Indication During therapy with Immune checkpoint inhibitors (INVIDIa-2) study investigated the clinical effectiveness of influenza vaccination in patients with advanced cancer receiving ICIs, enrolled in 82 Italian centers from October 2019 to January 2020. The primary endpoint was the time-adjusted incidence of influenza-like illness (ILI) until April 30, 2020. Secondary endpoints regarded ILI severity and vaccine safety.ResultsThe study enrolled 1279 patients; 1188 patients were evaluable for the primary endpoint analysis. Of them, 48.9% (581) received influenza vaccination. The overall ILI incidence was 8.2% (98 patients). Vaccinated patients were significantly more frequently elderly (p<0.0001), males (p=0.004), with poor European Cooperative Oncology Group performance status (p=0.009), affected by lung cancer (p=0.01), and by other non-cancer comorbidities (p<0.0001) when compared with unvaccinated. ILI incidence was not different basing on influenza vaccination: the time-to-ILI was similar in vaccinated and unvaccinated patients (p=0.62). ILI complications were significantly less frequent for patients receiving the vaccination (11.8% vs 38.3% in unvaccinated, p=0.002). ILI-related intravenous therapies were significantly less frequent in vaccinated patients than in unvaccinated (11.8% vs 29.8%, p=0.027). ILI lethality was, respectively, 0% in vaccinated and 4.3% in unvaccinated patients. Vaccine-related adverse events were rare and mild (1.5%, grades 1–2).ConclusionThe INVIDIa-2 study results support a positive recommendation for influenza vaccination in patients with advanced cancer receiving immunotherapy.

show abstract

Immunogenicity and safety of influenza vaccination in cancer patients receiving checkpoint inhibitors targeting PD-1 or PD-L1

Cited by 32 publications

References 15 publications

Cancer Management during COVID-19 Pandemic: Is Immune Checkpoint Inhibitors-Based Immunotherapy Harmful or Beneficial?

Cancer Management during COVID-19 Pandemic: Is Immune Checkpoint Inhibitors-Based Immunotherapy Harmful or Beneficial?

Immune-checkpoint inhibitors from cancer to COVID‑19: A promising avenue for the treatment of patients with COVID‑19 (Review)

INfluenza Vaccine Indication During therapy with Immune checkpoint inhibitors: a multicenter prospective observational study (INVIDIa-2)

Contact Info

Product

Resources

About